AARON'S COMPANY INC. O.N.

VANCOUVER, BC / ACCESS Newswire / May 20, 2025 / Aton Resources Inc. (TSXV:AAN) ("Aton" or the "Company") updates investors on the results of its ongoing diamond drilling programme at the Abu Marawat deposit ("Abu Marawat"), located within the retained exploration areas of the Company's Abu Marawat Concession (the "Concession") in the Eastern Desert of Egypt. Highlights: To date 95 diamond drill holes have been drilled at Abu Marawat, for a total of 7,917m.» Mehr auf accessnewswire.com

ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan April 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9, 2025 in San Diego, CA. The presentations showcase long-term data of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile.» Mehr auf globenewswire.com

WASHINGTON , April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025.  The following will be presented: April 9, 2025   Presentation Title: "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics This poster describes the data around a novel breakthrough therapeutic (VCA-894A) customized to a specific genetic mutation of a patient with Charcot-Marie-Tooth disease type 2S (CMT2S).» Mehr auf prnewswire.com